02.02.12
Merck
4Q Revenues: $12.3 billion (+2%)
4Q Earnings: $1.5 billion (loss of $531 million 4Q10)
FY Revenues: $48.0 billion (+4%)
FY Earnings: $6.3 billion (earnings were $982 million FY10)
Comments: Pharmaceutical sales were $10.8 billion in the quarter (+3%) and $41.3 billion for the year (+5%). Singulair sales rose 8% to $1.5 billion in the quarter and $5.5 billion for the year (+10%). Januvia sales were up 42% in the quarter to $960 million and up 39% to $3.3 billion for the year. Janumet sales were up 34% in the quarter and 43% for the year to $386 million and $1.4 billion, respectively. Isentress sales were up 24% in the quarter and 25% for the year to $387 million and $1.4 billion, respectively. Gardasil sales were up 24% in the quarter to $274 million and up 22% for the year to $1.2 billion. Cozaar/Hyzaar sales were $427 million in the quarter (+3%) and $1.7 billion for the year (-21%) due to loss of exclusivity in the U.S. Remicade sales were down 28% in the quarter to $511 million and down 2% to $2.7 billion for the year, due to the July 2011 transfer of some exclusive marketing rights for Remicade and Simponi to Johnson & Johnson. Merck retained rights in Europe, Russia and Turkey. Vytorin sales were down 16% in the quarter to $475 million and down 7% for the year to $1.9 billion, related to certain safety concerns. Earnings in 2010 reflect the impact of acquisition-related costs, and restructuring costs.
4Q Revenues: $12.3 billion (+2%)
4Q Earnings: $1.5 billion (loss of $531 million 4Q10)
FY Revenues: $48.0 billion (+4%)
FY Earnings: $6.3 billion (earnings were $982 million FY10)
Comments: Pharmaceutical sales were $10.8 billion in the quarter (+3%) and $41.3 billion for the year (+5%). Singulair sales rose 8% to $1.5 billion in the quarter and $5.5 billion for the year (+10%). Januvia sales were up 42% in the quarter to $960 million and up 39% to $3.3 billion for the year. Janumet sales were up 34% in the quarter and 43% for the year to $386 million and $1.4 billion, respectively. Isentress sales were up 24% in the quarter and 25% for the year to $387 million and $1.4 billion, respectively. Gardasil sales were up 24% in the quarter to $274 million and up 22% for the year to $1.2 billion. Cozaar/Hyzaar sales were $427 million in the quarter (+3%) and $1.7 billion for the year (-21%) due to loss of exclusivity in the U.S. Remicade sales were down 28% in the quarter to $511 million and down 2% to $2.7 billion for the year, due to the July 2011 transfer of some exclusive marketing rights for Remicade and Simponi to Johnson & Johnson. Merck retained rights in Europe, Russia and Turkey. Vytorin sales were down 16% in the quarter to $475 million and down 7% for the year to $1.9 billion, related to certain safety concerns. Earnings in 2010 reflect the impact of acquisition-related costs, and restructuring costs.